SCHEMBL5886370

SCHEMBL5886370

CN(C)CC(Cl)CN(C)C

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.33
HRH1 P35367 1/20 0.33
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7893161 0.96 TDP1 (0.36) HTR2AHRH1TDP1
SCHEMBL1067179 0.83
SCHEMBL9617235 0.83
SCHEMBL10762385 0.81
Hydrochloric Acid SCHEMBL27282115 0.81
SCHEMBL2932820 0.77
SCHEMBL135840 0.74
SCHEMBL8060724 0.74
SCHEMBL27669385 0.74 ALDH1A1 (0.33) HTR2AHRH1TDP1
Hydrochloric Acid SCHEMBL377772 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0406837-B1 Cationic polysaccharides and reagents for their preparation NAT STARCH CHEM INVEST (US) 1995-10-18 EP claimed
US-5227481-A Cationic polysaccharides and reagents for their preparation NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) 1993-07-13 US claimed
EP-0406837-A2 Cationic polysaccharides and reagents for their preparation National Starch and Chemical Investment Holding Corporation (US) 1991-01-09 EP claimed
US-7132419-B2 Pharmaceutical compounds XENOVA LIMITED (GB) 2006-11-07 US disclosed
US-20050143383-A1 Pharmaceutical compounds XENOVA LIMITED (GB) 2005-06-30 US disclosed
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 US disclosed
EP-1240148-A1 BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II Xenova Limited (GB) 2002-09-18 EP disclosed
WO-2001046157-A1 BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II XENOVA LIMITED (GB) 2001-06-28 WO disclosed
US-6193843-B1 PREPARED BY REACTING A POLYSACCHARIDE WITH A POLYCATIONIC REAGENT HAVING ONE POLYSACCHARIDE REACTIVE GROUP AND AT LEAST TWO CATIONIC GROUPS; SUITABLE REAGENTS INCLUDE POLYCATIONIC ALKYL, ARYL, ALKARYL, CYCLOALIPHATIC, OR HETEROCYCLIC AMINES NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION 2001-02-27 US disclosed
EP-0406837-B1 Cationic polysaccharides and reagents for their preparation NAT STARCH CHEM INVEST (US) 1995-10-18 EP disclosed
US-5349089-A N-/3-/haloethylethyl/aminopropyl/N,N,N-trimethylammonium salt NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) 1994-09-20 US disclosed
US-5227481-A Cationic polysaccharides and reagents for their preparation NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) 1993-07-13 US disclosed
EP-0406837-A2 Cationic polysaccharides and reagents for their preparation National Starch and Chemical Investment Holding Corporation (US) 1991-01-09 EP disclosed
US-4661618-A STIMULATION OF BRAIN CELLS AND MENTAL ACTIVITY; ANTIAGING AGENTS BIOGAL GYOGYSZERGYAR (HU) 1987-04-28 US disclosed
EP-0127000-B1 1,3-BIS(DIMETHYLAMINO)-2-PROPYL-4-CHLOROPHENOXYACETATE, ITS ADDITION SALTS, PROCESS FOR ITS PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING THE AFORE-MENTIONED COMPOUNDS BIOGAL GYOGYSZERGYAR (HU) 1987-01-07 EP disclosed
EP-0127000-A1 1,3-Bis(dimethylamino)-2-propyl-4-chlorophenoxyacetate, its addition salts, process for its production and pharmaceutical preparations containing the afore-mentioned compounds BIOGAL GYOGYSZERGYAR (HU) 1984-12-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143383-A1 Pharmaceutical compounds CHRNA10, OPRM1, SCN10A HTR2A 308/4885HRH1 174/4885TDP1 4765/4885
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II TOP1, TOP2A, TOP2B HTR2A 1304/4885HRH1 1145/4885TDP1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.